Clinical predictors of survival in patients with relapsed/refractory small-cell lung cancer treated with checkpoint inhibitors: a German multicentric real-world analysis.

Jan A StratmannRadha TimalsinaAkin AtmacaVivian RoseryNikolaj FrostJürgen AltCornelius F WallerNiels ReinmuthGernot RohdeFelix C SaalfeldAaron Becker von RoseFabian AckerLukas AspacherMiriam MöllerMartin Sebastian

Published in: Therapeutic advances in medical oncology (2022)

CPI in patients with relapsed or refractory (R/R) SCLC is of limited value in an overall patient cohort; however, long-term survival, in particular with CPI combination strategies, is possible. Clinical characteristics allow a more differentiated subgroup selection, in particular patients with low NLR showed less benefit from CPI in R/R SCLC.

Keyphrases

small cell lung cancer
acute lymphoblastic leukemia
acute myeloid leukemia
multiple myeloma
hodgkin lymphoma
diffuse large b cell lymphoma
dna damage
case report
cell cycle
randomized controlled trial
clinical trial
brain metastases
free survival
phase iii